Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

Katherine V. Houser, Grace Chen, Cristina Carter, Michelle C. Crank, Thuy Nguyen, Maria Claudia Burgos Florez, Nina M. Berkowitz, Floreliz Mendoza, Cynthia S. Hendel, Ingelise J. Gordon, Emily E. Coates, Sandra Vazquez, Judy Stein, Christopher L. Case, Heather Lawlor, Kevin Carlton, Martin R. Gaudinski, Larisa Strom, Amelia R. Hofstetter, C. Jason Liang, Sandeep Narpala, Christian Hatcher, Rebecca A. Gillespie, Adrian Creanga, Masaru Kanekiyo, Julie E. Raab, Sarah F. Andrews, Yi Zhang, Eun Sung Yang, Lingshu Wang, Kwanyee Leung, Wing‐Pui Kong, Alec W. Freyn, Raffael Nachbagauer, Peter Palese, Robert T. Bailer, Adrian B. McDermott, Richard A. Koup, Jason G. Gall, Frank Arnold, John R. Mascola, Barney S. Graham, Julie E. Ledgerwood, the VRC 316 Study Team, Joseph P. Casazza, LaSonji A. Holman, Abidemi O. Ola, Pamela Costner, Jennifer Cunningham, Brenda Larkin, Laura Novik, Jamie Saunders, William Whalen, Xiaolin Wang, Aba Mensima Eshun, Alison Taylor, K.-C. Cheng, Carolyn M. Laurençot, Josephine H. Cox, Sandra Sitar, Lam Le, Iris Pittman, Olga Vasilenko, Ro Shauna Rothwell, Galina V. Yamshchikov, Eugenia Burch, Somia P. Hickman, Olga Trofymenko, Catina Boyd, Preeti Apte, Cora Trelles Cartagena, Renunda Hicks, Pernell Williams, Zana Blaku, Colin Tran